A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Novartis

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Prostate Cancer; Bone Metastases

Treatments: Drug: MCS110

Study type: Interventional

Funder types: Industry

Identifiers

NCT00757757

CMCS110A2101

Details and patient eligibility

About

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Enrollment: 3 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment
• 18 years old and over

Exclusion criteria

• Plan to be on cytotoxic or biologic therapy during study
• Active dental problems
• Active heart complications
• Active infection
• Patients with moderate to severe swelling due to fluid

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

MCS110

Experimental group

Treatment:

Drug: MCS110